Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
GLP-1 Agonists Market: COMPANY EVALUATION MATRIX In the GLP-1 agonists market matrix, Novo Nordisk (Star) stands out as the leading player, supported by a strong product portfolio and global market presence, driving widespread usage in diabetes and obesity management
For example, a Cleveland Clinic study from June 2025, involving 7,881 participants, found that high-dose tirzepatide users lost 18.0% of their body weight in one year, semaglutide users lost 13.7%, and those who discontinued early (within three months) lost just 3.6%
Who should avoid it Pregnant or breastfeeding women should avoid it due to insufficient safety data
We believe that wellness starts with trusttrust in the ingredients, trust in the science, and trust in the results
The risk is lower when combined with metformin alone
2016b;375:1834
US$ 25.28
US$ 29.76
US$ 29.22
US$ 24.16
